| Trial ID: | L0208 |
| Source ID: | NCT04697810
|
| Associated Drug: |
Namodenoson
|
| Title: |
Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Namodenoson|Drug: Placebo
|
| Outcome Measures: |
Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS)|Adverse events (AEs)|Alanine transaminase (ALT) mean|Steady-state blood level of namodenoson
|
| Sponsor/Collaborators: |
Can-Fite BioPharma
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
114
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
December 10, 2021
|
| Completion Date: |
April 15, 2023
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 9, 2022
|
| Locations: |
Saroka University Medical Center, Be'er Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel
|
| URL: |
https://ClinicalTrials.gov/show/NCT04697810
|
